WO2022137125A1 - Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis - Google Patents

Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis Download PDF

Info

Publication number
WO2022137125A1
WO2022137125A1 PCT/IB2021/062115 IB2021062115W WO2022137125A1 WO 2022137125 A1 WO2022137125 A1 WO 2022137125A1 IB 2021062115 W IB2021062115 W IB 2021062115W WO 2022137125 A1 WO2022137125 A1 WO 2022137125A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
group
combination therapy
ester
use according
Prior art date
Application number
PCT/IB2021/062115
Other languages
English (en)
French (fr)
Inventor
David Alan Fraser
Original Assignee
Northsea Therapeutics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northsea Therapeutics B.V. filed Critical Northsea Therapeutics B.V.
Priority to CN202180086806.5A priority Critical patent/CN116829139A/zh
Priority to MX2023007347A priority patent/MX2023007347A/es
Priority to JP2023537995A priority patent/JP2023554524A/ja
Priority to EP21839683.6A priority patent/EP4267124A1/en
Priority to CA3201254A priority patent/CA3201254A1/en
Priority to KR1020237024993A priority patent/KR20230128307A/ko
Priority to AU2021405273A priority patent/AU2021405273A1/en
Priority to US18/258,620 priority patent/US20240325336A1/en
Publication of WO2022137125A1 publication Critical patent/WO2022137125A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present disclosure relates to combination therapies for treating non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other hepatic disorders characterized by fibrosis and/or hepatic inflammation in a subject in need thereof. Further, the present disclosure relates to methods of treating non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other hepatic disorders characterized by fibrosis and/or hepatic inflammation in a subject in need thereof using such combination therapies.
  • the combination therapies comprise unsaturated fatty acids with an oxygen incorporated in the p-position and an a-substituent.
  • Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NASH) are frequently used interchangeably despite the fact that NAFLD encompasses a much broader spectrum of liver disease including isolated hepatosteatosis (> 5% of hepatocytes histologically). Hepatosteatosis is most likely a relatively benign disorder when not accompanied by an inflammatory response and cellular damage.
  • NAFLD nonalcoholic steatohepatitis
  • NASH nonalcoholic steatohepatitis
  • NASH hepatocellular carcinoma
  • alcoholic liver disease also known as alcoholic fatty liver disease
  • ALD alcoholic liver disease
  • ASH alcoholic hepatitis
  • chronic hepatitis with hepatic fibrosis or cirrhosis.
  • the origins of ASH and NASH may differ, the hepatic response to the respective chronic insult has many similarities, including the pro-inflammatory and pro-fibrotic cascades involving macrophage activation and cytokine production and the resultant activated stellate cells, i.e., proliferating myofibroblasts.
  • omega-3 fatty acids are sufficiently potent to treat and/or reverse NASH where pronounced histological/inflammatory changes have developed (Sanyal AJ, et al; EPE-A Study Group, Gastroenterology. 2014 Aug; 147(2):377-84.e1).
  • fibrosis component of NASH and ASH is relevant to successfully treating progressed forms of these indications as hepatic fibrosis can further progress to cirrhosis, which in turn is associated with a highly increased morbidity and mortality. It also represents the major hard endpoint in clinical studies of chronic liver diseases. For example, emerging data suggests fibrosis, rather than NASH per se, to be the most important histological predictor of both liver and non-liver related death. Additionally, cirrhosis is a strong cofactor of primary liver cancer.
  • WO2016173923A1 discloses that sulphur-containing structurally modified fatty acids like 2- ethyl-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11 ,14,17-pentaenylthio)butanoic acid (Compound N) may be useful in the treatment of NASH. This was based on the finding that Compound N was superior to rosiglitazone, a PPAR-gamma agonist, in preventing diet-induced hepatic fibrosis. It also indicated that Compound N prevented the influx of inflammatory cells into the liver. It was demonstrated that Compound N was effective in reducing fibrosis (as measured by hydroxyproline/proline ratio) in APOE*3Leiden.CETP mice, a model that develops a very mild heaptic fibrotic response.
  • WO2019111048 of BASF AS discloses that oxygen-containing structurally modified fatty acids like 2-(((5Z,8Z,11Z,14Z,17Z)- icosa-5,8,11 ,14,17-pentaen-1 -yl)oxy)butanoic acid (Compound A) may be useful in the treatment of NASH and ASH.
  • Compound A was found to address multipe aspects of NASH, including hepatic steatosis, inflammation, and fibrosis.
  • combination therapeutics may be desirable for targeting different pathways contributing to these diseases.
  • the present disclosure provides a combination therapy comprising a structurally enhanced fatty acid containing oxygen and one or more additional active agents for the therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH).
  • NASH non-alcoholic steatohepatitis
  • ASH alcoholic steatohepatitis
  • the present disclosure likewise provides methods of treating NASH and/or ASH in a subject in need thereof comprising administering an oxygen-containing structurally modified fatty acid and at least one additional active agent.
  • the present disclosure provides a combination therapy comprising a first compound of Formula (II) wherein Ri is selected from a C10-C22 alkenyl having 3-6 double bonds;
  • R 2 and R 3 are the same or different and are selected from the group of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; wherein R 2 and R 3 can be connected in order to form a cycloalkane like cyclopropane, cyclobutane, cyclopentane or cyclohexane;
  • X is a carboxylic acid or a derivative thereof; wherein the derivative is a carboxylate, such as a carboxylic ester; a glyceride; an anhydride; a carboxamide; a phospholipid; or a hydroxymethyl; or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt thereof, and at least one additional active agent chosen from a glucagon-like peptide 1 (GLP-1) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist, for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH).
  • GLP-1 glucagon-like peptide 1
  • ACC acetyl-CoA carboxylase
  • FXR farnesoid X receptor
  • the present disclosure likewise relates to a method of treating NASH and/or ASH in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a first compound of Fromula (II): wherein Ri, R 2 , R 3 , and X are defined as described above, and further comprising administering at least one additional active agent chosen from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist.
  • the GLP-1 receptor agonist is semaglutide
  • the ACC inhibitor is firsocostat
  • the FXR agonist is obeticholic acid (OCA).
  • R 2 and R 3 are the same or different and may be selected from a group of substituents consisting of a hydrogen atom, an alkyl group, an alkoxy group, an alkenyl group; or R 2 and R 3 can be connected in order to form a cycloalkane like cyclopropane, cyclobutane, cyclopentane or cyclohexane;
  • X represents a carboxylic acid or a derivative thereof, wherein the derivative is a carboxylic ester, a glyceride or a phospholipid; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt thereof.
  • the present disclosure also relates to a combination therapy comprising a first compound of Formula (I): wherein R 2 and R3 and X are defined as for Formula II. More particularly,
  • R 2 and R 3 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic Ci-C 6 alkyl groups
  • X is a carboxylic acid or a derivative thereof, wherein the derivative is a carboxylic ester, a glyceride, or a phospholipid; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt thereof, and at least one additional active agent chosen from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist, for use in the therapeutic and/or prophylactic treatment of NASH and/or ASH.
  • the GLP-1 receptor agonist is semaglutide
  • the ACC inhibitor is firsocostat
  • the FXR agonist is obeticholic acid (OCA).
  • the present disclosure relates to a method of treating NASH and/or ASH in a subject in need thereof, comprising administering a pharmaceutically effective amount of a first compound of Formula (I): wherien wherein R 2 and R3 and X are defined as described above, and further comprising administering at least one additional active agent chosen from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist.
  • the compound of Formula (I) is 2- (((5Z, 8Z,11Z,14Z,17Z)-icosa-5, 8,11 ,14, 17-pentaen-1-yl)oxy)butanoic acid (Compound A):
  • the present disclosure also provides a combination therapy comprising 2-
  • the GLP-1 receptor agonist is semaglutide
  • the ACC inhibitor is firsocostat
  • the FXR agonist is obeticholic acid (OCA).
  • the present disclosure also relates to the effects of the combination therapies in subjects with NASH and/or ASH.
  • the use of the combination therapy decreases the level of plasma and/or liver triglycerides in the subject. In some embodiments, the use of the combination therapy decreases the level of plasma and/or liver cholesterol in the subject. In some embodiments, the use of the combination therapy reduces hepatic steatosis in the subject. In some embodiments, the use of the combination therapy reduces hepatic inflammation in the subject. In some embodiments, the use of the combination therapy reduces hepatic fibrosis in the subject. In some embodiments, the use of the combination therapy reverses steatohepatitis in the subject.
  • Figs. 1A-1 B depict the effects of 8 weeks of administration of Compound A, semaglutide, firsocostat, OCA, and combinations thereof, on the relative body weight (Fig. 1 A) and liver weight (Fig. 1B) in a CDAA/high-fat diet mouse model.
  • the same experimental conditions apply to the results depicted in the remaining figures.
  • Figs. 2A-2B depict the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof, on the levels of plasma alanine transaminase (ALT) (Fig. 2A) and plasma aspartate transaminase (AST) (Fig. 2B).
  • ALT plasma alanine transaminase
  • AST plasma aspartate transaminase
  • Figs. 3A-3B depict the effects of Compound A, semaglutide, firsocostate, OCA, and combinations thereof, on plasma triglycerides (TG) (Fig. 3A) and plasma total cholesterol (TC) (Fig. 3B).
  • Figs. 4A-4B depict the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof, on the relative levels of liver TC (Fig. 4A) and liver TG (Fig. 4B).
  • Figs. 5A-5B depict the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof, on the hepatic steatosis area (relative levels of liver lipids) (Fig. 5A) and the percentage of hepatocytes with lipid droplets (Fig. 5B).
  • Fig. 6 depicts the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof, on hepatic steatosis scores.
  • Figs. 7A-7B depict the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof on the number of hepatic inflammatory cells (Fig. 7A) and hepatic inflammatory foci (Fig. 7B).
  • Figs. 8A-8B depict the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof, on lobular inflammation (Fig. 8A) and NAFLD activity scores (Fig. 8B).
  • Figs. 9A-9B depict the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof, on the relative levels of liver hydroxyproline (HP) (Fig. 9A) and hepatic area of galectin-3 expression (Fig. 9B).
  • Figs. 10A-10C depicts the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof, on the hepatic fibrotic area determined by picrosirius red (PSR) (Fig. 10A), hepatic sinusoidal fibrotic area determined by PSR (Fig. 10B) and hepatic periportal fibrotic area determined by PSR (Fig. 10C).
  • PSR picrosirius red
  • Fig. 10B hepatic sinusoidal fibrotic area determined by PSR
  • Fig. 10C hepatic periportal fibrotic area determined by PSR
  • Figs. 11A-11B depicts the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof, on the hepatic area of collegen 1 a1 (Col1a1 ) expression (Fig. 11A) and hepatic area of a-smooth muscle actin (a-SMA) expression (Fig. 11 B).
  • Fig. 12 depicts the effects of Compound A, semaglutide, firsocostat, OCA, and combinations thereof on the hepatic fibrosis stage.
  • embodiments and features described in the context of one aspect of the present disclosure also apply to the other aspects of the disclosure.
  • the embodiments applying to the method of treating non-alcoholic steatohepatitis or alcohol steatohepatitis according to the present disclosure also apply to the aspect directed to compounds and/or combination therapies for use in treating non-alcoholic steatohepatitis or alcohol steatohepatitis, all according to the present disclosure.
  • treat include any therapeutic or prophylactic application that can benefit a human or non-human mammal. Both human and veterinary treatments are within the scope of the present disclosure. Treatment may be responsive to an existing condition or it may be prophylactic, i.e. , preventative.
  • preventing and/or treating” and “therapeutic and/or prophylactic treatment of” may interchangeably be used.
  • the compounds and/or combination therapies of the present disclosure will be used for treating, i.e., therapeutic treatment of NASH or ASH.
  • the compositions will be used for prophylactic treatment of NASH or ASH, for example in cases where a patient has one or multiple risk factors associated with NASH or ASH.
  • reverse and regress are used herein with respect to treatment that reduces the severity of an existing condition, or a parameter of that condition, to a more favorable level than the level at the start of treatment.
  • administer refers to (1 ) providing, giving, dosing and/or prescribing by either a health practitioner or his authorized agent or under his direction compounds and/or combination therapies according to the present disclosure, and (2) putting into, taking or consuming by the human patient or person himself or herself, or non-human mammal compositions according to the present disclosure.
  • administered in combination and “co-administration” or “coadministration” are used interchangeably and refer to administration of a (a) compound of Formula (I) or (II), or a pharmaceutically acceptable salt, solvate, or solvate of such a salt of any of the foregoing; and (b) at least one additional active agent, together in a coordinated fashion.
  • the coadministration can be simultaneous administration, sequential administration, overlapping administration, interval administration, continuous administration, or a combination thereof.
  • the mode of administration may be different for the compounds and the additional agent(s), and the co-administration includes any mode of administration, such as oral, subcutaneous, sublingual, transmucosal, parenteral, intravenous, intra-arterial, intra-peritoneal, buccal, sublingual, topical, vaginal, rectal, ophthalmic, otic, nasal, inhaled, and transdermal, or a combination thereof.
  • parenteral administration include but are not limited to intravenous (IV) administration, intraarterial administration, intramuscular administration, subcutaneous administration, intraosseous administration, intrathecal administration, or a combination thereof.
  • the compound of Formula (I) or (II) and the additional active agent can be independently administered, e.g., orally or parenterally. In some embodiments, the compound of Formula (I) or (II) and the additional active agent are both administered orally. In some embodiment, the compound of Formula (I) or (II) is administered orally; and the additional active agent is administered parenterally. The parenteral administration may be conducted via injection or infusion. In some embodiments, the method and/or use of the present disclosure are directed to the therapeutic and/or prophylactic treatment of NASH or ASH using at least two different active agents, the compound of Formula (I) or (II), and an additional active agent, respectively. The at least two active agents can be seen as a “combined product” or “combination therapy”, wherein the agents are e.g., separately packed and wherein both agents are required to achieve the optimal intended effect.
  • pharmaceutically effective amount means an amount sufficient to achieve the desired pharmacological and/or therapeutic effects, i.e., an amount of the disclosed compound that is effective for its intended purpose, and is interchangeable with the term “therapeutically effective amount.” While individual subject/patient needs may vary, the determination of optimal ranges for effective amounts of the disclosed compound is within the skill of the art. Generally, the dosage regimen for treating a disease and/or condition with the compounds and/or combination therapies presently disclosed may be determined according to a variety of factors such as the type, age, weight, sex, diet, and/or medical condition of the subject/patient.
  • composition means a compound or combination of compounds according to the present disclosure in any form suitable for medical use.
  • the compounds of Formula (I) and Formula (II) of the present disclosure may exist in various stereoisomeric forms, including enantiomers, diastereomers, or mixtures thereof. It will be understood that the present disclosure encompasses all optical isomers of the compounds of Formula (I) and (II) as well as mixtures thereof. Hence, compounds of Formual (I) and (II) of the present disclosure that exist as diastereomers, racemates, and/or enantiomers are within the scope of the present disclosure.
  • the combination therapies of the present disclosure comprise a first compound of Formula (II) (II) wherein Ri is selected from a C10-C22 alkenyl having 3-6 double bonds;
  • R2 and R3 are the same or different and may be selected from a group of substituents consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group, where R 2 and R 3 can be connected in order to form a cycloalkane like cyclopropane, cyclobutane, cyclopentane or cyclohexane;
  • X represents a carboxylic acid or a derivative thereof, wherein the derivative is a carboxylate, such as a carboxylic ester; a glyceride; an anhydride; a carboxamide; a phospholipid; or a hydroxymethyl; or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt thereof; and at least one additional active agent, for use in therapeutic and/or prophylactic treatment of nonalcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH).
  • NASH nonalcoholic steatohepatitis
  • ASH alcoholic steatohepatitis
  • the present disclosure is likewise directed to combination therapies comprising a first compound of Formula (II) wherein R1 is selected from a C10-C22 alkenyl having 3-6 double bonds;
  • R 2 and R 3 are the same or different and may be selected from a group of substituents consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group, where R 2 and R 3 can be connected in order to form a cycloalkane like cyclopropane, cyclobutane, cyclopentane or cyclohexane;
  • X represents a carboxylic acid or a derivative thereof, wherein the derivative is a carboxylate, such as a carboxylic ester; a glyceride; an anhydride; a carboxamide; a phospholipid; or a hydroxymethyl; or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt thereof; and at least one additional active agent, for use in therapeutic and/or prophylactic treatment of fatty liver disease.
  • the fatty liver disease is non-alcoholic fatty liver disease (NAFLD).
  • the fatty liver disease is alcoholic fatty liver disease (ALD).
  • the fatty liver disease is not accompanied by an inflammatory response and cellular damage.
  • the at least one additional active agent is selected from a glucagon-like peptide 1 (GLP-1) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist.
  • GLP-1 glucagon-like peptide 1
  • ACC acetyl-CoA carboxylase
  • FXR farnesoid X receptor
  • the at least one additional active agent is selected from a GLP-1 receptor agonist. In some embodiments, the at least one additional active agent is selected from an ACC inhibitor. In some embodiments, the at least one additional active agent is selected from a FXR agonist.
  • the GLP-1 receptor agonist is semaglutide.
  • the ACC inhibitor is firsocostat.
  • the FXR agonist is obeticholic acid (OCA).
  • the at least one additional active agent is semaglutide. In some embodiments, the at least one additional active agent is firsocostat. In some embodiments, the at least one additional active agent is obeticholic acid (OCA).
  • OCA obeticholic acid
  • Ri is a C18-C22 alkenyl having 3-6 double bonds, such as 5 or 6 double bonds. In some embodiments one double bond is in the omega-3 position.
  • R2 and R3 are independently chosen from a hydrogen atom and linear, branched, and/or cyclic Ci-C 6 alkyl groups.
  • at least one of R 2 and R 3 is chosen from a hydrogen atom, a methyl group, an ethyl group, an n- propyl group, an isopropyl group, a butyl group and a pentyl group.
  • the first compound X represents a carboxylic acid or a carboxylic ester; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt thereof.
  • a method of treating NASH and/or ASH in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of a first compound of Formula (II): (II) wherein Ri , R 2 , R3, and X are defined as described above; or prodrug thereof; or a pharmaceutically acceptable salt, solvate, or solvate of such salt thereof; and at least one additional active agent.
  • the at least one additional active agent is selected from a glucagon-like peptide 1 (GLP-1 ) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist.
  • the present disclosure provides a method of treating non-alcoholic steatohepatitis or alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a combination therapy comprising a pharmaceutically effective amount of a first compound of Formula (I): wherein R 2 , R3 and X are defined as for Formula (II) and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist.
  • the GLP-1 receptor agonist is semaglutide
  • the ACC inhibitor is firsocostat
  • the FXR agonist is obeticholine.
  • R 2 and R3 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic Ci-C 6 alkyl groups
  • X is a carboxylic acid or a carboxylic ester; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt of any of the foregoing.
  • the present disclosure similarly provides for methods of treating fatty liver disease in a subject in need thereof, comprising to the subject a combination therapy comprising a pharmaceutically effective amount of a first compound of Formula (I) or (II), wherein R1 , R 2 , R3, and X are defined as described above, and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist.
  • the GLP-1 receptor agonist is semaglutide
  • the ACC inhibitor is firsocostat
  • the FXR agonist is obeticholine.
  • the fatty liver disease is non-alcoholic fatty liver disease (NAFLD).
  • the fatty liver disease is alcoholic fatty liver disease (ALD). In some embodiments, the fatty liver disease is not accompanied by an inflammatory response and cellular damage.
  • the present disclosure provides a combination therapy comprising a first compound of Formula (I): wherein R 2 , R3 and X are defined as for Formula (II) and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist, for use in treating NASH and/or ASH.
  • the GLP-1 receptor agonist is semaglutide
  • the ACC inhibitor is firsocostat
  • the FXR agonist is obeticholine.
  • the present disclosure provides a combination therapy comprising a first compound of Formula (I): wherein R 2 , R3 and X are defined as for Formula (II) and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist, for use in treating fatty liver disease.
  • the GLP-1 receptor agonist is semaglutide
  • the ACC inhibitor is firsocostat
  • the FXR agonist is obeticholine.
  • the fatty liver disease is non-alcoholic fatty liver disease (NAFLD).
  • the fatty liver disease is alcoholic fatty liver disease (ALD).
  • the fatty liver disease is not accompanied by an inflammatory response and cellular damage.
  • R 2 and R3 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic Ci-Ce alkyl groups;
  • X is a carboxylic acid or a carboxylic ester; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt of any of the foregoing.
  • R 2 and R 3 are independently selected from the group of a hydrogen atom, a methyl group, an ethyl group, a n-propyl group, an isopropyl group, a butyl group and a pentyl group.
  • R 2 and R 3 are independently selected from the group of a hydrogen atom, a methyl group, and an ethyl group.
  • one of R 2 and R 3 is a hydrogen atom and the other one of R 2 and R 3 is chosen from a Ci-C 3 alkyl group. In one embodiment, one of R 2 and R 3 is a hydrogen atom and the other one of R 2 and R 3 is selected from a methyl group and an ethyl group. In some embodiments, one of R 2 and R 3 is a hydrogen atom and the other one is an ethyl group.
  • R 2 and R 3 are, in some embodiments, independently Ci-C 6 alkyl groups. In some embodiments both R 2 and R 3 are Ci-C 3 alkyl groups. In some embodiments R 2 and R 3 are the same or different and each are independently chosen from a methyl group, an ethyl group, an n-propyl group, and an isopropyl group. In some embodiments R 2 and R 3 are the same and are selected from a pair of methyl groups, a pair of ethyl groups, a pair of n-propyl groups and a pair of isopropyl groups. In at least one embodiment R 2 and R 3 are ethyl groups.
  • one of R 2 and R 3 is a methyl group and the other one is an ethyl group. In some embodiments, one of R 2 and R 3 is an ethyl group and the other one is a n-propyl group.
  • the compounds of Formula (I) or (II) are present in their various stereoisomeric forms, such as an enantiomer (R or S), a diastereomer, or mixtures thereof. In at least one embodiment, the compounds are present in racemic form.
  • the compound according to Formula (I) or (II) is a salt of a counter-ion with at least one stereogenic center, or ester of an alcohol with at least one stereogen ic center
  • the compound may have multiple stereocenters.
  • the compounds of the present disclosure may exist as diastereomers.
  • the compounds of the present disclosure are present as at least one diastereomer.
  • the compound of Formula (II) or (I) is administered in combination with firsocostat. In some embodiments, the compound of Formula (II) or (I) is administered in combination with OCA. In some embodiments, the compound of Formula (II) or (I) is administered in combination with semaglutide.
  • the compound of Formula (I) or (II) of the present disclosure is 2- (((5Z,8Z, 11 Z, 14Z,17Z)-icosa-5,8,1 1 ,14,17-pentaen-1 -yl)oxy)butanoic acid (Compound A):
  • the compound of Formula (I) or (II) of the present disclosure is 2- (((5Z, 8Z,11Z,14Z,17Z)-icosa-5, 8,11 ,14, 17-pentaen-1-yl)oxy)butanoic acid (Compound A) is present in its S and/or R form represented by the formulas:
  • 2-(((5Z,8Z,11 Z, 14Z,17Z)-icosa-5,8,11 ,14,17-pentaen-1 -yl)oxy)butanoic acid (Compound A) is administered in combination with at least one additional active agent selected from firsocostat, OCA, and semaglutide.
  • the combination therapy comprises a compound of Formula (I) or (II) and semaglutide. In some embodiments, the combination therapy comprises a compound of Formula (I) or (II) and fircosostat. In some embodiments, the combination therapy comprises a compound of Formula (I) or (II) and OCA. In some embodiments, the compound of Formula (I) or (II) is 2-(((5Z,8Z,11Z.14Z, 17Z)-icosa-5, 8,11 , 14,17-pentaen-1 -yl)oxy)butanoic acid (Compound A).
  • the use of the combination therapy decreases the level of plasma and/or liver triglycerides in the subject. In some embodiments, the use of the combination therapy decreases the level of plasma and/or liver cholesterol in the subject. In some embodiments, the use of the combination therapy reduces hepatic steatosis in the subject. In some embodiments, the use of the combination therapy reduces hepatic inflammation in the subject. In some embodiments, the use of the combination therapy reduces hepatic fibrosis in a subject. In some embodiments, the use of the combination therapy reverses steato hepatitis.
  • the combination of Compound A and semaglutide significantly reduced the fibrotic area of liver, and the fibrotic sinusoidal area, as determined with picrosirius red (PSR) compared with vehicle, as well as compared with both Compound A and semaglutide alone (Figs. 10A and 10B).
  • the combination of Compound A and OCA significantly reduced the hepatic area expressing a-SMA compared to vehicle as well as Compound A and OCA alone (Fig. 11 B).
  • this combination had a significant effect despite neither Compound A nor OCA significantly affecting a-SMA liver content compared with vehicle.
  • the CDAA-induced NASH model results described herein support the notion that the combination therapies presented herein are effective in the treatment of NASH-related complications. This finding was also supported by the effects of the combination therapies on inflammatory responses, as well as the effects on steatosis.
  • Compound A in combination with firsocostat, Compound A in combination with semaglutide, and Compound A in combination with OCA all reduced the number of inflammatory cells and inflammatory foci to below the baseline level that existed prior to initiating therapy (Figs. 7A and 7B).
  • Compound A alone also reduced these indicators of inflammation below the baseline level.
  • the combination of Compound A and semaglutide surprisingly reduced inflammatory cells and inflammatory foci significantly more than Compound A alone, despite semaglutide alone not having a significant effect compared to vehicle.
  • the combination therapies also significantly reduced steatosis.
  • treatment with Compound A in combination with firsocostat, Compound A in combination with semaglutide and Compound A in combination with OCA all show a greater decrease of liver triglyceride levels than compared to the groups that were treated with a monotherapy of these individual compounds (Fig. 4B).
  • the combination of Compound A and semaglutide resulted in significantly lower levels of liver triglycerides than either agent alone, despite semaglutide alone not significantly affecting liver triglyceride levels compared to vehicle.
  • it was unexpected that the combination of Compound A and firsocostate greatly and significantly reduced liver triglyceride levels compared to either agent alone.
  • the combination therapies of the present disclosure comprising compounds of Formula (II) or Formula (I) and at least one additional active agent chosen from a glucagon-like peptide 1 (GLP-1) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist, may be administered to treat and/or reverse non-alcoholic steatohepatitis (NASH), or other hepatic disorders characterized by hepatic steatosis, fibrosis, and/or inflammation.
  • NASH non-alcoholic steatohepatitis
  • the treatment of NASH may be prophylactic.
  • the compounds may be administered to treat at least one disease, condition or risk factor associated with NASH.
  • the treatment of at least one disease, condition, or risk factor associated with NASH may be prophylactic.
  • the anti-inflammatory and anti-fibrotic effects of the disclosed compounds described herein in NASH models are thus relevant for the treatment and/or reversal of ASH, in particular, the prevention of progression and induction of regression of advanced ASH and associated fibrosis.
  • the combination therapies comprising compounds of Formula (II), or Formula (I), and at least one additional active agent chosen from a glucagon-like peptide 1 (GLP-1) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist may be administered to treat and/or reverse ASH.
  • the treatment of ASH may be prophylactic.
  • the compounds may be administered to treat at least one disease, condition or risk factor associated with ASH.
  • the treatment of at least one disease, condition, or risk factor associated with ASH may be prophylactic.
  • the combination therapy comprising a compound of Formula (I) or (II) and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist is used to decrease the level of plasma triglycerides and/or cholesterol in a subject who has NASH or ASH.
  • the combination therapy comprising a compound of Formula (I) or (II) and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist decreases hepatic steatosis in a subject with NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment.
  • the combination therapy reduces relative hepatic triglyceride and/or cholesterol levels in a subject who has NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment.
  • the combination therapy reduces the hepatic steatosis area of liver lipids in a subject who has NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment. In some embodiments, the combination therapy reduces the percentage of hepatocytes with lipid droplets in a subject who has NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment. In some embodiments, the combination therapy reduces the steatosis score in a subject who has NASH or ASH compared with a subject who has NASH or ASH who has not received therapeutic treatment. In some embodiments the combination therapy comprises a compound of Formula (I) or (II) and semaglutide.
  • the combination therapy comprises a compound of Formula (I) or (II) and firsocostat. In some embodiments, the combination therapy comprises a compound of Formula (I) or (II) and OCA. In some embodiments, the compound of Formula (I) or (II) is Compound A.
  • the combination therapy comprising a compound of Formula (I) or (II) and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist decreases hepatic steatosis in a subject with fatty liver disease compared with a subject fatty liver disease who has not received therapeutic treatment.
  • the combination therapy reduces relative hepatic triglyceride and/or cholesterol levels in a subject who has fatty liver disease compared with a subject with fatty liver disease who has not received therapeutic treatment.
  • the combination therapy reduces the hepatic steatosis area of liver lipids in a subject who has fatty liver disease compared with a subject with fatty liver disease who has not received therapeutic treatment. In some embodiments, the combination therapy reduces the percentage of hepatocytes with lipid droplets in a subject who has fatty liver disease compared with a subject with NASH or ASH who has not received therapeutic treatment. In some embodiments, the combination therapy reduces the steatosis score in a subject who has fatty liver disease compared with a subject who has fatty liver disease who has not received therapeutic treatment. In some embodiments the combination therapy comprises a compound of Formula (I) or (II) and semaglutide.
  • the combination therapy comprises a compound of Formula (I) or (II) and firsocostat. In some embodiments, the combination therapy comprises a compound of Formula (I) or (II) and OCA. In some embodiments, the compound of Formula (I) or (II) is Compound A.
  • the fatty liver disease is non-alcoholic fatty liver disease (NAFLD). In some embodiments, the fatty liver disease is alcoholic fatty liver disease (ALFD). In some embodiments, the fatty liver disease is not accompanied by an inflammatory response and cellular damage.
  • NAS NAFLD activity score
  • the combination therapy comprising a compound of Formula (I) or (II) and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist decreases hepatic inflammation in a subject with NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment.
  • the combination therapy decreases the number of hepatic inflammatory cells and/or the number of hepatic inflammatory foci in a subject with NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment.
  • the combination therapy comprises a compound of Formula (I) or (II) and semaglutide.
  • the combination therapy comprises a compound of Formula (I) or (II) and firsocostat. In some embodiments, the combination therapy comprises a compound of Formula (I) or (II) and OCA. In some embodiments, the compound of Formula (I) or (II) is Compound A.
  • the combination therapy comprising a compound of Formula (I) or (II) and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist decreases the NAFLD activity score (NAS) in a subject with NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment.
  • the combination therapy comprises a compound of Formula (I) or (II) and semaglutide.
  • the combination therapy comprises a compound of Formula (I) or (II) and firsocostat.
  • the combination therapy comprises a compound of Formula (I) or (II) and OCA.
  • the compound of Formula (I) or (II) is Compound A.
  • the NAFLD activity score (NAS) of a subject is determined as outlined in Kleiner et al., Hepatology, 2005; 41 and as described in the biological examples herein.
  • the combination therapy comprising a compound of Formula (I) or (II) and at least one additional active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist decreases hepatic fibrosis in a subject with NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment.
  • the combination therapy reduces the level of relative liver galectin-3 in a subject with NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment.
  • the combination therapy reduces the liver hydroxyproline content in a subject.
  • the combination therapy reduces the hepatic fibrotic area determined by PSR in a subject with NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment. In some embodiments, the combination therapy reduces the hepatic sinusoidal fibrotic area determined by PSR in a subject with NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment. In some embodiments, the combination therapy reduces the hepatic area expressing oc-smooth muscle actin in a subject with NASH or ASH compared with a subject with NASH or ASH who has not received therapeutic treatment. In some embodiments the combination therapy comprises a compound of Formula (I) or (II) and semaglutide.
  • the combination therapy comprises a compound of Formula (I) or (II) and firsocostat. In some embodiments, the combination therapy comprises a compound of Formula (I) or (II) and OCA. In some embodiments, the compound of Formula (I) or (II) is Compound A.
  • the combination therapy comprising a compound of Formula (II) and at least one additional active agent selected from GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist, further comprises a third or more additional active agent(s) independently chosen from angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, apoptosis signal-regulating kinase-1 (ASK1 ) inhibitors, caspase inhibitors, cathepsin B inhibitors, CCR2 chemokine antagonists, CCR5 chemokine antagonists, chloride channel stimulators, cholesterol solubilizers, diacyl glycerol O-acyltransferase 1 (DGAT1) inhibitors, dipeptidyl peptidase IV (DPP IV) inhibitors, fibroblast-growth factor (FGF)-21 agonists, anti-CD3 mAb, galectin-3 inhibitors, glutathione precursors, hepatitis C virus NS3 protease
  • a method of treating non-alcoholic steatohepatitis and/or alcoholic steatohepatitis in a subject in need thereof comprising administering to the subject a combination therapy comprising a compound of Formula (II) and at least one additional active agent selected from a glucagon-like peptide 1 (GLP-1 ) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist 1 .
  • the combination therapy comprises a compound of Formula (I) or (II) and semaglutide.
  • the combination therapy comprises a compound of Formula (I) or (II) and firsocostat. In some embodiments, the combination therapy comprises a compound of Formula (I) or (II) and OCA. In some embodiments, the compound of Formula (I) or (II) is Compound A.
  • administration of the combination therapy in the methods of the present disclosure is by simultaneous administration. In some embodiments, administration of the combination therapy in the methods of the present disclosure is by sequential administration. In some embodiments, administration of the combination therapy in the methods of the present disclosure is by overlapping administration. In some embodiments, administration of the combination therapy in the methods of the present disclosure is by interval administration. In some embodiments, administration of the combination therapy in the methods of the present disclosure is by continuous administration.
  • the present disclosure is also directed to use of the described combination therapies in the therapeutic and/or prophylactic treatment of NASH and/or ASH.
  • the present disclosure is likewise directed to use of the described combination therapies in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of NASH and/or ASH.
  • a combination therapy of the present disclosure reduces plasma triglyceride levels by about 20%, 25%, 30%, 35%, or 40% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment. In some embodiments, a combination therapy of the present disclosure reduces plasma triglyceride levels by 20-30%, 30-40%, or 10-40%. In some embodiments, a combination therapy of the present disclosure reduces plasma total cholesterol levels by by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment.
  • a combination therapy of the present disclosure reduces plasma total cholesterol levels by 20-30%, 20-25%, 25-30%, 30- 40%, 30-35%, 35-40%, 40-50%, 40-45%, 45-50%, 50-60%, 50-55%, 55-60%, 60-70%, 60-65%, 65-70%, 70-80%, 70-75%, or 75-80%.
  • a combination therapy of the present disclosure reduces liver total cholesterol levels by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment. In some embodiments, a combination therapy of the present disclosure reduces liver total cholesterol levels by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in a subject with NAFLD or ALD as compared to a subject with NAFLD or ALD who does not receive treatment. In some embodiments, both subjects have fatty liver disease that is not accompanied by an inflammatory response and cellular damage.
  • a combination therapy of the present disclosure reduces liver total cholesterol levels by 20-30%, 20-25%, 25-30%, 30- 40%, 30-35%, 35-40%, 40-50%, 40-45%, 45-50%, 50-60%, 50-55%, 55-60%, 60-70%, 60-65%, 65-70%, 70-80%, 70-75%, 75-80%, 80-90%, 80-85%, or 85-90%.
  • a combination therapy of the present disclosure reduces liver triglyceride levels by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment. In some embodiments, a combination therapy of the present disclosure reduces liver triglyceride levels by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in a subject with NAFLD or ALD as compared to a subject with NAFLD or ALD who does not receive treatment. In some embodiments, both subjects have fatty liver disease that is not accompanied by an inflammatory response and cellular damage.
  • a combination therapy of the present disclosure reduces liver triglyceride levels by 20-30%, 20-25%, 25-30%, 30-40%, 30-35%, 35- 40%, 40-50%, 40-45%, 45-50%, 50-60%, 50-55%, 55-60%, 60-70%, 60-65%, 65-70%, 70-80%, 70-90%, 70-75%, 75-80%, 80-90%, 80-85%, or 85-90%.
  • a combination therapy of the present disclosure reduces hepatic steatosis area by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment. In some embodiments, a combination therapy of the present disclosure reduces hepatic steatosis area by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in a subject with NAFLD or ALD disease as compared to a subject with NAFLD or ALD who does not receive treatment. In some embodiments, both subjects have fatty liver disease that is not accompanied by an inflammatory response and cellular damage.
  • a combination therapy of the present disclosure reduces hepatic steatosis area by 20-30%, 20-25%, 25-30%, 30-40%, 30-35%, 35- 40%, 40-50%, 40-45%, 45-50%, 50-60%, 50-55%, 55-60%, 60-70%, 60-65%, 65-70%, 70-80%, 70%-90%, 70-75%, 75-80%, 80-90%, 80-85%, or 85-90%.
  • a combination therapy of the present disclosure reduces the percentage of hepatocytes with lipid droplets by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment. In some embodiments, a combination therapy of the present disclosure reduces the percentage of hepatocytes with lipid droplets by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in a subject with NAFLD or ALD as compared to a subject with NAFLD or ALD who does not receive treatment. In some embodiments, both subjects have fatty liver disease that is not accompanied by an inflammatory response and cellular damage.
  • a combination therapy of the present disclosure reduces the percentage of hepatocytes with lipid droplets by 20-30%, 20-25%, 25-30%, 30-40%, 30-35%, 35-40%, 40-50%, 40-45%, 45-50%, 50-60%, 50-55%, 55-60%, 60-70%, 60-65%, 65-70%, 70-80%, 70-90%, 70-75%, 75-80%, 80- 90%, 80-85%, or 85-90%.
  • a combination therapy of the present disclosure reduces inflammatory cells by about 10%, 20%, 30%, 40%, or 45% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment. In some embodiments, a combination therapy of the present disclosure reduces inflammatory cells by 10-20%, 10-15%, 15-20%, 20-30%, 20-25%, 25-30%, 30-40%, 30-50%, 30-35%, 35-40%, 40-50%, or 40-45%. In some embodiments, a combination therapy of the present disclosure reduces inflammatory foci by about 20%, 30%, 40%, 50%, 60%, 70%, or 75% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment.
  • a combination therapy of the present disclosure reduces inflammatory foci by 20- 30%, 20-25%, 25-30%, 30-40%, 30-35%, 35-40%, 40-50%, 40-45%, 45-50%, 50-60%, 50-55%, 55-60%, 60-70%, 60-80%, 60-65%, 65-70%, 70-80%, or 70-75%.
  • a combination therapy of the present disclosure reduces hepatic area expressing galectin-3 by about 20%, 30%, 40%, or 50% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment. In some embodiments, a combination therapy of the present disclosure reduces hepatic area expressing galectin-3 by 20-30%, 20-25%, 25-30%, 30-40%, 30-35%, 35-40%, 40-50%, 40-45%, or 45- 50%.
  • a combination therapy of the present disclosure reduces liver hydroxyproline levels by about 20%, 30%, or 40% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment. In some embodiments, a combination therapy of the present disclosure reduces liver hydroxyproline levels by 20-30%, 20-25%, 25-30%, 20-40%, 30-40%, 30-35%, or 35-40%.
  • a combination therapy of the present disclosure reduces hepatic fibrotic area determined by PSR by about 20%, 30%, 40%, or 50% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment.
  • a combination therapy of the present disclosure reduces hepatic fibrotic area determined by PSR 20-30%, 20-25%, 25-30%, 30-40%, 30-50%, 30-35%, 35-40%, 40-50%, 40- 45%, or 45-50%.
  • a combination therapy of the present disclosure reduces hepatic sinusoidal fibrotic area determined by PSR by about 20%, 30%, or 40%.
  • a combination therapy of the present disclosure reduces hepatic fibrotic sinusoidal fibrotic area by PSR 20-30%, 20-25%, 25-30%, 30-40%, 30-35%, or 35-40%.
  • a combination therapy of the present disclosure reduces hepatic area expressing a-SMA by about 5%, 10%, 20%, or 30% in a subject with NASH or ASH as compared to a subject with NASH or ASH who does not receive treatment. In some embodiments, a combination therapy of the present disclosure reduces hepatic area expressing a-SMA by 5-10%, 10-20%, 10-15%, 15-20%, 20-30%, 20-25%, or 25-30%.
  • Some embodiments relate to a compound of Formula (II) as a monotherapy for use in reversing heaptic steatosis in a subject with NAFLD or ALD.
  • a compound of Formual (II) reverses hepatic steatosis area in a subject with NAFLD or ALD.
  • the fatty liver disease is not not accompanied by an inflammatory response and cellular damage.
  • Some embodiments relate to a compound of Formula (II) as a monotherapy for use in reversing hepatic steatosis and inflammation in a subject with NASH or ASH.
  • a compound of Formula (II) reverses hepatic steatosis area in a subject with NASH or ASH.
  • a compound of Formula (II) reverses hepatic inflammation in a subject with NASH or ASH.
  • Compounds of Formula (I) and Formula (II) can be prepared as described, for example, in PCT Applications W02009/061208, WO2010/128401 , WO2011/089529, WO2016/156912, WO2019/111048, and according to Examples below.
  • Compound A can be prepared as described, for example, in PCT Applications W02010/128401 , WO2014/132135, and WO2019/111048 and according to Example 2 below.
  • These publications are incorporated herein by reference. The Examples provided below are exemplary and one skilled in the art would understand how to apply these general methods to arrive at other compounds within the scope of Formula (I) and Formula (II).
  • Compounds of the present disclosure may be in the form of a pharmaceutically acceptable salt or ester.
  • the compounds of Formula (I) and Formula (II) may be in the form of esters, such as a phospholipid, a glyceride or a Ci-C 6 -alkyl ester.
  • the ester is chosen from a glyceride or a Ci-Ce-alkyl ester.
  • the ester is chosen from a triglyceride, a 1 ,2-diglyceride, a 1 ,3-diglyceride, a 1- monoglyceride, a 2-monoglyceride, a methyl ester, an ethyl ester, a propyl ester, an isopropyl ester, an n-butyl ester and a tert-butyl ester.
  • the compound of Formula (I) is present as a methyl ester, an ethyl ester, an isopropyl ester, a n-butyl ester or a tert-butyl ester, for example as a methyl ester or an ethyl ester.
  • esters represented by Formula (I) e.g., ethyl esters
  • Salts suitable for the present disclosure include, but are not limited to, salts of NH 4 + ; metal ions such as Li + , Na + , K + , Mg 2+ , or Ca 2+ ; a protonated primary amine such as tertbutyl ammonium, (3S,5S,7S)-adamantan-1 -ammonium, 1 ,3-dihydroxy-2-(hydroxymethyl)propan-2-ammonium, a protonated aminopyridine (e.g., pyridine-2-ammonium); a protonated secondary amine such as diethylammonium, 2,3,4,5,6-pentahydroxy-N-methylhexan-1-ammonium, N-ethylnaphthalen-1 - ammonium, a protonated tertiary amine such as 4-methylmorpholin-4-ium, a protonated quaternary amine such as 2-hydroxy-N,N,N-trimethylethan-1 -aminium and a
  • salts of a diprotonated diamine such as ethane-1 ,2-diammonium or piperazine-1 ,4-diium.
  • Other salts according to the present disclosure may comprise protonated Chitosan:
  • the salts are chosen from a sodium salt, a calcium salt, and a choline salt.
  • the salt is a sodium salt or a calcium salt.
  • the present disclosure provides for a method of treating NASH or ASH in a subject in need thereof, comprising co-administering to the subject a pharmaceutically effective amount of a compound of Formula (I) or Formula (II) and at least one additional active agent chosen from a glucagon-like peptide 1 (GLP-1 ) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist.
  • GLP-1 glucagon-like peptide 1
  • ACC acetyl-CoA carboxylase
  • FXR farnesoid X receptor
  • the subject may be a human or a non-human mammal.
  • the compounds presently disclosed may be co-administered as a medicament, such as in a pharmaceutical composition.
  • compositions comprising a compound of Formula (II) or Formula (I), such as Compound A and at least one additional active agent chosen from a glucagon-like peptide 1 (GLP-1) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist, for use in treating non-alcoholic steatohepatitis.
  • GLP-1 glucagon-like peptide 1
  • ACC acetyl-CoA carboxylase
  • FXR farnesoid X receptor
  • the composition presently disclosed may optionally further comprise at least one non-active pharmaceutical ingredient, i.e., excipient.
  • Non-active ingredients may solubilize, suspend, thicken, dilute, emulsify, stabilize, preserve, protect, color, flavor, and/or fashion active ingredients into an applicable and efficacious preparation, such that it may be safe, convenient, and/or otherwise acceptable for use.
  • excipients include, but are not limited to, solvents, carriers, diluents, binders, fillers, sweeteners, aromas, pH modifiers, viscosity modifiers, antioxidants, extenders, humectants, disintegrating agents, solution-retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, coloring agents, dispersing agents, and preservatives.
  • Excipients may have more than one role or function or may be classified in more than one group; classifications are descriptive only and are not intended to be limiting.
  • the at least one excipient may be chosen from corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, ethanol, glycerol, sorbitol, polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose, and fatty substances such as hard fat or suitable mixtures thereof.
  • compositions presently disclosed further comprise at least one pharmaceutically acceptable antioxidant, e.g., tocopherol such as alpha- tocopherol, beta -tocopherol, gamma-tocopherol, and cfe/ta-tocopherol, or mixtures thereof, BHA such as 2-tert-butyl-4-hydroxyanisole and 3-tert-butyl-4-hydroxyanisole, or mixtures thereof and BHT (3,5-di-tert-butyl-4-hydroxytoluene), or mixtures thereof.
  • tocopherol such as alpha- tocopherol, beta -tocopherol, gamma-tocopherol, and cfe/ta-tocopherol, or mixtures thereof
  • BHA such as 2-tert-butyl-4-hydroxyanisole and 3-tert-butyl-4-hydroxyanisole, or mixtures thereof
  • BHT 3,5-di-tert-butyl-4-hydroxytoluene
  • the compounds of Formula (I) and (II) presently disclosed may be formulated in one or more oral administration forms, e.g., tablets or gelatin soft or hard capsules.
  • the dosage forms can be of any shape suitable for oral administration, such as spherical, oval, ellipsoidal, cubeshaped, regular, and/or irregular shaped.
  • Conventional formulation techniques known in the art may be used to formulate the compounds according to the present disclosure.
  • the composition may be in the form of a gelatin capsule or a tablet.
  • the first component of the combined product i.e., the compound of Formula (I) or (II) may be administered or formulated in any manner as described above.
  • the second component of the combined product, the additional active agent may be formulated as is suitable for the type of agent it is, and depends on several factors, including the mode of administration of the agent.
  • the co-administration of the combination therapy is by simultaneous administration. In some embodiments, the co-administration is by sequential administration. In some embodiments, the co-administration is by overlapping administration. In some embodiments, the co-administration is by interval administration. In some embodiments, the coadministration is by continuous administration.
  • the present disclosure relates to combination therapies for use in treating NASH and/or ASH that comprise at least one compound of Formula (I) or (II) and at least one additional active agent.
  • the at least one additional active agent is chosen from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist.
  • a suitable daily dosage of a compound of Formula (I) or a compound of Formula (II) may range from about 5 mg to about 4 g, such as from about 5 mg to about 2 g.
  • the daily dose ranges from about 10 mg to about 1 .5 g, from about 50 mg to about 1 g, from about 100 mg to about 1 g, from about 150 mg to about 900 mg, from about 50 mg to about 800 mg, from about 100 mg to about 800 mg, from about 100 mg to about 600 mg, from about 150 to about 550 mg, or from about 200 to about 500 mg.
  • the daily dose ranges from about 200 mg to about 600 mg.
  • the daily dose is about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, or about 900 mg.
  • the compound(s) may be administered, for example, once, twice, or three times per day.
  • the compound of Formula (I) is administered in an amount ranging from about 200 mg to about 800 mg per dose. In at least one embodiment, the compounds are administered once per day. In at least one embodiment, the compounds are administered once per day at a dose of 750 mg. In some embodiments, compounds are administered once per day at a dose of 600 mg. In some embodiments, compounds are administered once per day at a dose of 500 mg. In some embodiments, compounds are administered once per day at a dose of 300 mg. In some embodiments, compounds are administered once per day at a dose of 250 mg. In some embodiments, compounds are administered once per day at a dose of 300 mg or 600 mg.
  • the compound of Formula (ll) is administered in an amount ranging from about 200 mg to about 800 mg per dose.
  • the compounds are administered once per day.
  • the compounds are administered once per day at a dose of 750 mg.
  • the compounds are administered once per day at a dose of 600 mg.
  • the compounds are administered once per day at a dose of 500 mg.
  • the compounds are administered once per day at a dose of 300 mg.
  • the compounds are administered once per day at a dose of 250 mg.
  • the compounds are administered once per day at a dose of 300 mg or 600 mg.
  • the at least one additional active agent of the disclosed combination therapies is a GLP-1 receptor agonist.
  • GLP-1 receptor agonists or incretin mimetics, are agonists of the Glucagon-like peptide-1 receptor. This class of drugs is typically used for the treatment of type 2 diabetes.
  • a non-limiting example list of GLP-agonists includes: exenatide, liraglutide, lixisenatide, albiglutide, du laglutide, taspoglutide and semaglutide.
  • the at least one additional active agent of the combination therapy is semaglutide.
  • the human equivalent dose can be calculated from the doses used in pre-clinical mouse models by using a mouse to human multiple of 12.3 (Nair et al., J Basic Clin Pharm, 2016, 7 :27- 31).
  • the at least one additional agent of the combination therapy is semaglutide.
  • the daily dose of semaglutide ranges from about 50 pg to about 500 pg, from about 75 pg to about 250 pg, from about 75 pg to about 150 pg, from about 100 pg to about 150 pg, from about 0.1 mg to about 10 mg, from about 0.2 mg to about 8 mg, from about 0.5 mg to about 7 mg, or from about 1 mg to about 5 mg.
  • semaglutide is administered at a daily dose of about 0.1 mg to about 0.2 mg.
  • semaglutide is administered a daily dose of about 75 pg to about 150 pg.
  • semaglutide is administered at a daily dose of about 75 pg to about 125 pg. Semaglutide may be administered, for example, once, twice, or three times per day. In some embodiments, semaglutide is administered once per day.
  • the daily dose of semaglutide is about 50 pg, about 75 pg, about 100 pg, about 125 pg, about 150 pg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 1 .5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, or about 10 mg.
  • semaglutide is administered once per day at a dose of 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg.
  • the at least one additional active agent of the disclosed combination therapies is an ACC inhibitor.
  • the ACC inhibitor is firsocostat.
  • the at least one additional agent of the combination therapy is firsocostat.
  • the daily dose of firsocostat ranges from about 5 mg to about 3 g, from about 50 mg to about 2.5 g, from about 100 mg to about 2 g, from about 500 mg to about 3 g, from about 1 g to about 2.5 g, from about 1 .5 g to about 2.5 g, from about 5 mg to about 500 mg, from about 10 mg to about 300 mg, from about 20 mg to about 200 mg, or from about 50 mg to 100 mg.
  • the daily dose of firsocostat is about 10 mg/kg to about 50 mg/kg.
  • the daily dose of firsocostat is about 15 mg/kg to about 40 mg/kg. In some embodiments, the daily dose of firsocostat is about 20 mg/kg to about 30 mg/kg. Firsocostat may be administered, for example, once, twice, or three times per day. In some embodiments, firsocostat is administered once per day.
  • the daily dose of firsocostat is about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 1 1 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, abou 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg.
  • the daily dose of firsocostat is about 1 g, about 1 .5 g, about 2 g, or about 2.5 g. In some embodiments, firsocostat is administered once per day at a dose of about 15 mg/kg, about 20 mg/kg, about 25 mg/k, about 30 mg/kg, about 500 mg, about 1 .5 g, about 2 g, or about 2.5 g.
  • the at least one additional active agent of the disclosed combination therapies is a FXR inhibitor.
  • the FXR inhibitor is obeticholic acid.
  • the at least one additional agent of the combination therapy is OCA.
  • the daily dose of OCA ranges ranges from about 0.5 mg to about 250 mg, from about 2 mg to about 250 mg, from about 5 mg to about 200 mg, from about 50 mg to about 200 mg, from about 100 mg to about 200 mg, from about 150 mg to about 200 mg, or from about 5 mg to 20 mg.
  • OCA is administered in a daily dose of about 170 mg.
  • OCA may be administered, for example, once, twice, or three times per day. In some embodiments, OCA is administered once per day.
  • the daily dose of OCA is about 0.5 mg, about 1 mg, about 1 .5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 10.5 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg.
  • OCA is administered once per day at a dose of 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg.
  • OCA is dministered at a daily dose of about 50 mg, about 60 mg, about 70 mg, about 90 mg, about 100 mg, about 110 mg, abouto 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, or about 200 mg. In some embodiments, OCA is administered once per day.
  • the combination therapies comprising at least one compound of Formula (I) or (II) and at least a second active agent selected from a GLP-1 receptor agonist, an ACC inhibitor, and a FXR agonist may be co-administered with a third or more further additional active agent.
  • the GLP-1 receptor agonist is semaglutide
  • the ACC inhibitor is firsocostat
  • the FXR agonist is OCA.
  • the third or more active agent is chosen from angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, apoptosis signal-regulating kinase-1 (ASK1) inhibitors, caspase inhibitors, cathepsin B inhibitors, CCR2 chemokine antagonists, CCR5 chemokine antagonists, chloride channel stimulators, cholesterol solubilizers, diacyl glycerol O-acyltransferase 1 (DGAT1 ) inhibitors, dipeptidyl peptidase IV (DPP IV) inhibitors, fibroblast-growth factor (FGF)-21 agonists, anti-CD3 mAb, galectin-3 inhibitors, glutathione precursors, hepatitis C virus NS3 protease inhibitors, HMG CoA reductase inhibitors, 1 Ip-hydroxysteroid dehydrogenase (I Ip-HSDI) inhibitors, heat shock protein (Hsp)47 inhibitors
  • ACE
  • the compound of Formula (II) or (I) is administered in combination with firsocostat and OCA. In some embodiments, the compound of Formula (II) or (I) is administered in combination with firsocostat and semaglutide. In some embodiments, the compound of Formula (II) or (I) is administered in combination with OCA and semaglutide. In some embodiments, the compound of Formula (II) or (I) is administered in combination with firsocostat, OCA and semaglutide. In some embodiments, the third or more active agent is a dipeptidyl peptidase inhibitor (DPP-4 antagonist). DPP-4 antagonists are a class of oral hypoglycemics that block DPP-4 (DPP-IV).
  • DPP-4 antagonists are a class of oral hypoglycemics that block DPP-4 (DPP-IV).
  • DPP-4 inhibitors can be used to treat diabetes mellitus type 2.
  • Glucagon increases blood glucose levels
  • DPP-4 inhibitors reduce glucagon and blood glucose levels.
  • the mechanism of DPP-4 inhibitors is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.
  • a non-limiting example list of dipeptidyl peptidase inhibitors includes: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, Alogliptin, Trelagliptin, Omarigliptin, Evogliptin, Dutogliptin.
  • the third or more additional agent is an omega-3 fatty acid.
  • the omega-3 fatty acid is typically a long chain polyunsaturated omega-3 fatty acid (LC n-3 PUFA).
  • LC n-3 PUFA long chain polyunsaturated omega-3 fatty acid
  • this includes at least one of (all-Z omega-3)-5,8,11 ,14,17-eicosapentaenoic acid (EPA) and (all-Z omega-3)- 4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof.
  • the n-3 PUFAs including the EPA and DHA, may be in different forms, and are presented in at least one of free fatty acid form; esterified form, such as C1 -C4 alkyl esters, and preferably ethyl ester; phospholipids; mono/di/tri-glycerides; and salts thereof.
  • the omega-3 fatty acid may be provided in the form of a composition, such as a composition for oral administration. Such composition may comprise at least 40%, such as at least 50%, 60%, 70% or 80% of the active omega-3 fatty acid.
  • the third or more additional active agent is a composition comprising at least one of EPA and DHA, preferably on ethyl ester form, in a concentration of at least 70%.
  • the third or more additional active agents are independently selected from the group of acetylsalicylic acid, alipogene tiparvovec, aramchol, atorvastatin, Bl 1467335, BLX-1002, BMS-986036, BMS-986020, cenicriviroc, cobiprostone, colesevelam, emricasan, enalapril, foramulab, GFT-505, GR-MD-02, GS-0976, GS-9674, hydrochlorothiazide, icosapent ethyl ester (ethyl eicosapentaenoic acid, EPA ethyl ester), IMM-124E, IVA337, K-877, KD-025, linagliptin, liraglutide, mercaptamine, MGL-3196, ND-L02-S0201 , obeticholic acid,
  • the third or more agent of the combined therapy be formulated as is suitable for the type of agent it is, and depends on several factors, including the mode of administration of the agent.
  • the dose of the third or more additional active agent(s) depends on the type of agent selected, and it should be in accordance with the approved amounts for the specific agent.
  • the combination therapies of the present disclosure comprising compounds of Formula (II) or Formula (I) and at least one additional active agent chosen from a glucagon-like peptide 1 (GLP-1) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist, may be administered to treat and/or reverse non-alcoholic steatohepatitis (NASH) or alcoholic steatohepatitis (ASH).
  • GLP-1 glucagon-like peptide 1
  • ACC acetyl-CoA carboxylase
  • FXR farnesoid X receptor
  • combination therapies comprising compounds of Formula (I), such as 2-(((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11 ,14,17-pentaen-1-yl)oxy)butanoic acid co-administered with at least one additional active agent chosen from a glucagon-like peptide 1 (GLP-1) receptor agonist, an acetyl-CoA carboxylase (ACC) inhibitor, and a farnesoid X receptor (FXR) agonist, have remarkably good pharmaceutical activity.
  • GLP-1 glucagon-like peptide 1
  • ACC acetyl-CoA carboxylase
  • FXR farnesoid X receptor
  • Nuclear magnetic resonance (NMR) shift values were recorded on a Bruker AvanceTM DPX 200 or 300 instrument with peak multiplicities described as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; q, quartet; p, pentet; m, multiplett; br, broad.
  • the mass spectra were recorded with a LC/MS spectrometer. Separation was performed using an Agilent 1100 series module on an Eclipse XDB-C18 2.1 x 150 mm column with gradient elution. As eluent were used a gradient of 5-95% acetonitrile in buffers containing 0.01% trifluoroacetic acid or 0.005% sodium formate.
  • the mass spectra were recorded with a GI956A mass spectrometer (electrospray, 3000 V) switching positive and negative ionization mode. Reported yields are illustrative and do not necessarily represent the maximum yield attainable.
  • Tetrabutylammonium chloride (0.55 g, 1 .98 mmol) was added to a solution of (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11 ,14,17-pentaen-1 -ol, (3.50 g, 12.1 mmol) in toluene (35 mL) at room temperature under nitrogen.
  • An aqueous solution of sodium hydroxide (50% (w/w), 11.7 mL) was added under vigorous stirring at room temperature, followed by t-butyl 2- bromobutyrate (5.41 g, 24.3 mmol).
  • Example 2 Preparation of 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17- pentaenyloxy)butanoic acid (Compound A): tert-Butyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11 ,14,17-pentaen-1 -yloxy)butanoate (19.6 g, 45.5 mmol) was dissolved in dichloromethane (200 mL) and placed under nitrogen. Trifluoroacetic acid (50 mL) was added and the reaction mixture was stirred at room temperature for one hour. Water was added and the aqueous phase was extracted twice with dichloromethane.
  • Compound A tert-Butyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11 ,14,17-pentaen-1 -yloxy)butanoate (19.6
  • CDAA/HFD choline-deficient high-fat diet
  • Col1 a1 collagen 1 a1 Fl: Food intake
  • HE or H&E Hematoxylin and eosin
  • PSR Picrosirius red or picro Sirius red PO: per oral gavage
  • QD Once a day
  • QW Once a week
  • SC Subcutaneous
  • the widely used methionine-choline deficient (MCD) diet consistently reproduces severe NASH-like hepatic inflammation and fibrosis in mice, it is also associated with severe weight-loss (loss of both skeletal muscle and fat mass). This is associated with an increased risk of death which presents major problems for long-term fibrogenesis experiments.
  • methionine 0.1%)
  • the CDAA dietary model overcomes these problems and has been demonstrated to mimic human NASH in both mice and rats by sequentially producing steatohepatitis, liver fibrosis and liver cancer with less severe loss of body weight.
  • mice Male mice (strain C57BI/6JRj) were fed choline deficient high-fat diets (45% of total calories from fat; “CDAA/high-fat” or “CDAA-HFD”).
  • the NASH inducing diet was instigated 6 weeks prior to the commencement of administration of active agents in order to evaluate treatment and reversal of NASH parameters.
  • the NASH inducing CDAA-HFD was continued for the 8 weeks of administration of the indicated active agents and combinations thereof.
  • the aim of this study was to evaluate the effects of 8 weeks of administration of Compound A, OCA, semaglutide, and firsocostat alone and in combination on metabolic parameters, hepatic pathology, and on NAFLD Activity Score including Fibrosis Stage in male CDAA-HFD mice.
  • CDAA-HFD fed mice received daily per oral (PO) treatment with vehicle, Compound A (112mg/kg), OCA (30mg/kg), semaglutide (30nmol/kg SC), firsocostat (5mg/kg), Compound A + Semaglutide (112mg/kg+30nmol/kg), Compound A + OCA (112mg/kg+30mg/kg), and Compound A + firsocostat (112mg/kg+5mg/kg) for 8 weeks.
  • Terminal liver biopsy were analyzed for histopathological scores. Terminal quantitative endpoints included plasma/liver biochemistry and liver histomorphometry. Table 2. Experimental Groups
  • NAS Liver samples stained with Hematoxylin and Eosin (H&E) or Piero Sirius Red (PSR) were scored for NAS components (steatosis, lobular inflammation, and ballooning degeneration) and fibrosis stage respectively using the clinical criteria outlined by Kleiner et al., Hepatology, 2005; 41 .
  • Total NAS represents the sum of scores for steatosis, inflammation, and ballooning, and ranges from 0-8.
  • NAS and fibrosis stage was determined by deep learning applications developed by Gubra (Denmark) using the VIS software (Visiopharm®, Denmark) for a more accurate and objective method for staging disease in DIO-NASH mouse models.
  • Another deep learning application detected nuclei of hepatocytes with lipid droplets, hepatocytes without lipids, ballooned hepatocytes, and inflammatory cells at 20x magnification. Inflammatory foci were defined as a cluster of >3 inflammatory cells.
  • the inflammation score of the liver tissue sample was the average score for all 20x fields. Steatosis score was calculated as percentage of hepatocytes with lipid droplets.
  • Fibrosis stage Scanned PSR stained slides were analyzed in several steps:
  • Periportal zone was defined as 100pm around the portal triads.
  • Fibrosis fibers were detected using the linear Bayesian image analysis method in the periportal and sinusoidal zones.
  • Immunohistochemistry (IHC) -positive staining was quantified by image analysis using the VIS software (Visiopharm®, Denmark) using two steps:
  • the quantitation of IHC-positive staining is calculated as an area fraction as follows:
  • IHC factional area quantification was assessed for galectin-3, collagen 1 A1 , and a-smooth muscle actin.
  • Hepatic factional area assessment with picrosirius red stain was determined using the same methods.
  • Fig. 1A experimental groups that received OCA, Semaglutide, and Compound A+OCA, and Compund A+semaglutide had decreased last recorded relative body weight compared to vehicle.
  • Fig. 1B groups administered Compound A, semaglutide, Compound A+firsocostat, and Compound A+semaglutide had decreased liver weight when compared to the untreated vehicle group.
  • Plasma alanine aminotransferase (ALT) (Fig. 2A) and aspartate transaminase (AST) (Fig. 2B) were measured after 8 weeks of administration of Compound A, OCA, semaglutide, firsocostat, and combination therapies.
  • Fig. 4A groups administered Compound A, OCA, Compound A+firsocostat, Compound A+OCA, and Compound A+semaglutide showed a significant decrease in relative levels of liver total cholesterol (normalized to liver weight) when compared to the untreated vehicle group.
  • the combination therapy groups all showed a significantly larger decrease than the groups receiving treatment with a single compound.
  • semaglutide alone did not significantly affect relative liver total cholesterol levels compared to the vehicle control
  • the combination of CompoundA+semaglutide had a significantly greater effect on relative liver total cholesteraol levels compared to Compound A alone.
  • Fig. 4B groups administered Compound A, OCA, Compound A+firsocostat, Compound A+OCA, and Compound A+semaglutide showed a significant decrease in relative levels liver triglycerides (normalized to liver weight) when compared to the untreated group.
  • Hepatic steatosis area (relative liver lipids) was quantified on H&E stained slides by image analysis using the VIS software (Visiopharm®, Denmark). VIS protocols are designed to analyze the virtual slides in two steps:
  • Fig. 5A groups administered Compound A, OCA, and the respective combination therapies showed a significant relative decrease in hepatic steatosis area when compared to the untreated vehicle group. All of the combination therapy groups showed a significantly larger decrease compared to groups treated with single compounds. In particular, Compound A+firsocostat significantly reduced hepatic steatosis area by a much greater extent than either compound alone. Additionally, while semaglutide did not have a significant effect on the hepatic steatosis area compared to vehicle, the combination of Compound A+semaglutide resulted in significantly lower hepatic steatosis area than Compound A alone.
  • the vehicle control group had a significanty lower hepatic steatosis area as compared to baseline, and the decreases obtained with the combination therapies, as well as Compound A, OCA, and firsocostat alone, were all significantly greater than the untreated vehicle group.
  • groups administered Compound A, firsocostat, and all of the combination therapy groups had significantly decreased percentages of hepatocytes with lipid droplets when compared to the untreated vehicle group. The percentage of hepatocytes with lipid droplets was determined using deep learning-based image analysis.
  • the groups receiving Compound A+semaglutide and Compound A+firsocostat had significantly larger decreases in percentages of hepatocytes with lipid droplets than the group receiving the respective individual agents alone.
  • semaglutide alone did not significantly affect the percentage of hepatocytes with lipid droplets compared to the vehicle control
  • the combination of CompoundA+semaglutide had a significantly greater effect than did Compound A alone.
  • the combination of Compound A+firsocostat had a much greater effect on the percentage of hepatocytes with lipid droplets than did either agent alone.
  • the number of inflammatory cells and inflammatory foci were determined by deep learningbased image analysis. As shown in Fig. 7A, the group administered Compound A and all three combination therapy groups had a significant decrease in the number of inflammatory cells (per mm 2 ) when compared to the untreated vehicle group, as well as when compared to the baseline levels. The group treated with Compound A+semaglutide had a significantly larger decrease in inflammatory cells compared to the group administered Compound A alone, despite semaglutide alone not having a significant effect compared to vehicle and baseline.
  • Fig. 7B shows that groups administred Compound A and the combination therapies had a significant decrease in inflammatory foci (per mm 2 ) when compared to the untreated vehicle group and compared to the baseline levels.
  • Fig. 8A shows the clinical lobular inflammation scores for all of the treatment groups.
  • Fig. 8B shows that groups administered Compound A, firsocostat, Compound A+firsocostat, and Compound A+semaglutide had significantly decreased NAFLD activity scores (NAS) when compared to the untreated vehicle group.
  • NAS NAFLD activity scores
  • Biological Example 7 Hepatic fibrosis
  • Hepatic area expressing galectin-3 which is a marker of hepatic inflammation and fibrosis, was determined by histological quantitative assessment. As shown in Fig. 9B, groups administered Compound A and all of the combination therapy groups had significanlty decreased galectin-3 hepatic fractional area when compared to the untreated vehicle group. The Compound A+semaglutide combination therapy group had a significantly greater decrease in hepatic fractional area expressing galectin-3 compared with Compound A alone, despite semaglutide alone not having a significant effect compared to vehicle.
  • this combination showed a regression effect such that it significantly reduced relative galectin-3 area below that of baseline, despite the semaglutide group having significantly increased galectin-3 expressing area compared to baseline.
  • the combination of Compound A and firsocostat also significantly reduced relative galectin-3 expressing area below baseline.
  • Hepatic fibrotic area was determined by staining with picrosirus red (PSR), which binds collagen, and histological quantitative assessment.
  • PSR picrosirus red
  • Fig. 10A groups administered Compound A and combination therapies had significantly decreased hepatic fibrotic area as determined by PSR staining when compared to the untreated vehicle group.
  • Semaglutide alone did not significantly affect hepatic fibrotic area.
  • Sinusoidal and periportal fibrotic area was determined using PSR and histological quantitative assessment and deep learning image analysis.
  • the Compound A+semaglutide significantly decreased sinusoidal fibrotic area when compared to the untreated vehicle group. Neither compound alone had a significant effect.
  • Fig. 10C shows the periportal fibrotic area for the various experimental groups.
  • Fig. 11 A shows the fractional area of collagen-1 (Col1 a1) expression for the various experimental groups.
  • Fig. 11 B shows fractional area of relative a-smooth muscle actin (a-SMA) expression for the various experimental groups.
  • the combination therapy Compound A+OCA significantly decreased liver a-SMA compared to the untreated vehicle group and compared to Compound A alone.
  • Fig. 12 shows the fibrosis stage scoring for each of the treatment groups.
  • Figs. 13A-13I show representative images of liver morphology of the various treatment groups at termination when stained with Piero Sirius Red.
  • Figs. 14A-14I show representative images of liver morphology of the various treatment groups at termination with H&E staining. The images were taken at a 20x magnification.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/IB2021/062115 2020-12-22 2021-12-21 Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis WO2022137125A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202180086806.5A CN116829139A (zh) 2020-12-22 2021-12-21 用于治疗非酒精性脂肪性肝炎的包含含氧的结构增强的脂肪酸的联合治疗剂
MX2023007347A MX2023007347A (es) 2020-12-22 2021-12-21 Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica.
JP2023537995A JP2023554524A (ja) 2020-12-22 2021-12-21 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法
EP21839683.6A EP4267124A1 (en) 2020-12-22 2021-12-21 Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
CA3201254A CA3201254A1 (en) 2020-12-22 2021-12-21 Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
KR1020237024993A KR20230128307A (ko) 2020-12-22 2021-12-21 비알코올성 지방간염의 치료를 위한 산소-함유 구조적으로개선된 지방산을 포함하는 병용요법
AU2021405273A AU2021405273A1 (en) 2020-12-22 2021-12-21 Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
US18/258,620 US20240325336A1 (en) 2020-12-22 2021-12-21 Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063128996P 2020-12-22 2020-12-22
US63/128,996 2020-12-22

Publications (1)

Publication Number Publication Date
WO2022137125A1 true WO2022137125A1 (en) 2022-06-30

Family

ID=79283090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/062115 WO2022137125A1 (en) 2020-12-22 2021-12-21 Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis

Country Status (9)

Country Link
US (1) US20240325336A1 (zh)
EP (1) EP4267124A1 (zh)
JP (1) JP2023554524A (zh)
KR (1) KR20230128307A (zh)
CN (1) CN116829139A (zh)
AU (1) AU2021405273A1 (zh)
CA (1) CA3201254A1 (zh)
MX (1) MX2023007347A (zh)
WO (1) WO2022137125A1 (zh)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
WO2010128401A1 (en) 2009-05-08 2010-11-11 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2011089529A1 (en) 2010-01-20 2011-07-28 Pronova Biopharma Norge As Salicylate fatty acid derivatives
WO2012059818A1 (en) * 2010-11-05 2012-05-10 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2014132135A2 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As Methods of preparing fatty acid derivatives
WO2014132134A1 (en) * 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2016156912A1 (en) 2015-04-01 2016-10-06 Pronova Biopharma Norge As Use of thia oxo compounds for lowering apo c3
WO2016173923A1 (en) 2015-04-28 2016-11-03 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
WO2017049173A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018126016A1 (en) * 2016-12-28 2018-07-05 Modunex Bio Corp. Combination therapy for nonalcoholic steatohepatitis (nash) and liver fibrosis
WO2018193006A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
US20190142905A1 (en) * 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
WO2019111048A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
WO2020061114A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
WO2010128401A1 (en) 2009-05-08 2010-11-11 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2011089529A1 (en) 2010-01-20 2011-07-28 Pronova Biopharma Norge As Salicylate fatty acid derivatives
WO2012059818A1 (en) * 2010-11-05 2012-05-10 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2014132135A2 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As Methods of preparing fatty acid derivatives
WO2014132134A1 (en) * 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2016156912A1 (en) 2015-04-01 2016-10-06 Pronova Biopharma Norge As Use of thia oxo compounds for lowering apo c3
WO2016173923A1 (en) 2015-04-28 2016-11-03 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
WO2017049173A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20190142905A1 (en) * 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
WO2018126016A1 (en) * 2016-12-28 2018-07-05 Modunex Bio Corp. Combination therapy for nonalcoholic steatohepatitis (nash) and liver fibrosis
WO2018193006A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
WO2019111048A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
WO2020061114A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRIEDMAN, SL, ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, vol. 23, no. 5, May 1999 (1999-05-01), pages 904 - 910
KLEINER ET AL., HEPATOLOGY, vol. 41, 2005
NAIR ET AL., J BASIC CLIN PHARM, vol. 7, 2016, pages 27 - 31
SANYAL AJ ET AL.: "EPE-A Study Group", GASTROENTEROLOGY, vol. 147, no. 2, August 2014 (2014-08-01), pages 377 - 84
SCORLETTI E ET AL.: "Effects of purified eicosapentaenoic and docosahexanoic acids in non-alcoholic fatty liver disease: Results from the WELCOME study", HEPATOLOGY, vol. 60, no. 4, October 2014 (2014-10-01), pages 1211 - 2

Also Published As

Publication number Publication date
CN116829139A (zh) 2023-09-29
MX2023007347A (es) 2023-08-16
EP4267124A1 (en) 2023-11-01
AU2021405273A1 (en) 2023-08-10
KR20230128307A (ko) 2023-09-04
US20240325336A1 (en) 2024-10-03
CA3201254A1 (en) 2022-06-30
JP2023554524A (ja) 2023-12-27

Similar Documents

Publication Publication Date Title
US20240156769A1 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
AU2018345817B2 (en) Combination therapy comprising an ACC inhibitor
CN113893239A (zh) 用于治疗肠渗透性过高的酪氨酸羟化酶抑制剂
JP7202892B2 (ja) 非アルコール性脂肪性肝疾患の予防及び治療薬
US11690848B2 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2022137125A1 (en) Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
JP7508447B2 (ja) 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸
EP3720431B1 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
TWI852999B (zh) 治療脂肪性肝病及/或脂肪性肝炎的方法
WO2017193563A1 (zh) 一种组合物及其用途、药物制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21839683

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3201254

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2023/007347

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2023537995

Country of ref document: JP

Ref document number: 202180086806.5

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023012567

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20237024993

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021839683

Country of ref document: EP

Effective date: 20230724

ENP Entry into the national phase

Ref document number: 2021405273

Country of ref document: AU

Date of ref document: 20211221

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112023012567

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230622